Ganaton Dosage Recommendations
For adults, the standard dosage of Ganaton (itopride) is 50 mg three times daily before meals, which can be initiated at 100 mg (2 tablets) three times daily and reduced to 50 mg (1 tablet) three times daily for maintenance, with adjustments based on age and symptom response 1.
Standard Adult Dosing
The FDA-approved dosing regimen follows this pattern 1:
- Initial dose: 100 mg (2 tablets) three times per day before meals on an empty stomach
- Maintenance dose: 50 mg (1 tablet) three times per day before meals on an empty stomach
- Total daily dose: 150 mg (maintenance) to 300 mg (initial)
This dosing schedule should be administered before meals to optimize gastric motility effects. The evidence consistently supports the 150 mg/day total dose (50 mg three times daily) across multiple clinical studies 2, 3, 4, 5.
Special Populations
Elderly Patients
The dosage should be appropriately decreased according to age 1. While the drug label indicates dose adjustment for elderly patients, it does not specify exact reductions. In clinical practice, starting with the lower maintenance dose (50 mg three times daily) rather than the higher initial dose would be prudent for elderly patients, given age-related changes in drug metabolism and clearance.
Renal and Hepatic Impairment
The provided evidence does not contain specific dosing recommendations for patients with moderate renal or hepatic impairment. The general guideline 6 addresses renally cleared medications but does not specifically include itopride. In the absence of specific guidance, caution dictates starting at the lower maintenance dose (50 mg three times daily) in patients with moderate organ impairment, with close monitoring for adverse effects.
Clinical Context
The 150 mg/day dosing (50 mg three times daily) has demonstrated:
- Significant symptom improvement in functional dyspepsia with response rates of 72-86% at 8 weeks 4, 5
- Improved quality of life scores 3
- Good tolerability with adverse event rates of only 1.5-3% 4, 5
The timing before meals is critical as itopride's prokinetic mechanism requires administration on an empty stomach to optimize gastric motility enhancement.
Safety Considerations
Monitor for prolactin elevations, which occur more frequently with itopride than placebo (approximately 3% of patients) 7. The drug is generally well-tolerated with minimal serious adverse events requiring discontinuation.